Quarterly report · Q2
4578.TEDINET S100OUL3
Period2022-01-01 → 2022-06-30
Filed2022-08-03
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥814.3bn | 2022-01-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥434.0bn | 2022-04-01 → 2022-06-30d | Cons. | Revenue IFRS |
| Revenue | ¥1.50T | 2021-01-01 → 2021-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥718.8bn | 2021-01-01 → 2021-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥382.0bn | 2021-04-01 → 2021-06-30d | Cons. | Revenue IFRS |
| Operating income | ¥67.1bn | 2022-01-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥46.4bn | 2022-04-01 → 2022-06-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥111.2bn | 2021-01-01 → 2021-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥61.1bn | 2021-04-01 → 2021-06-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥92.8bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥61.8bn | 2022-04-01 → 2022-06-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥163.6bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥119.2bn | 2021-01-01 → 2021-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥61.2bn | 2021-04-01 → 2021-06-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥69.8bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥46.5bn | 2022-04-01 → 2022-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥125.5bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥91.4bn | 2021-01-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥46.7bn | 2021-04-01 → 2021-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥71.5bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥47.3bn | 2022-04-01 → 2022-06-30d | Cons. | Profit loss IFRS |
| Net income | ¥93.7bn | 2021-01-01 → 2021-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥48.0bn | 2021-04-01 → 2021-06-30d | Cons. | Profit loss IFRS |
| Total assets | ¥3.10T | at 2022-06-30 | Cons. | Assets IFRS |
| Total assets | ¥2.82T | at 2021-12-31 | Cons. | Assets IFRS |
| Total assets | ¥2.73T | at 2021-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥839.5bn | at 2022-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥775.7bn | at 2021-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥2.26T | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.05T | at 2021-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.00T | at 2021-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.88T | at 2020-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥2.23T | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.01T | at 2021-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.97T | at 2021-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥456.8bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥410.7bn | at 2021-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥426.5bn | at 2021-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥356.9bn | at 2020-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥118.8bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥228.9bn | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥127.9bn | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥56.0bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥95.3bn | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥19.4bn | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥48.2bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥95.8bn | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥48.7bn | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥128.58 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥85.7 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥231.32 | 2021-01-01 → 2021-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥168.53 | 2021-01-01 → 2021-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥86.14 | 2021-04-01 → 2021-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥128.54 | 2022-01-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥85.65 | 2022-04-01 → 2022-06-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥231.15 | 2021-01-01 → 2021-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥167.68 | 2021-01-01 → 2021-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥85.29 | 2021-04-01 → 2021-06-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 71.8% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.3% | at 2021-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 72.0% | at 2021-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 88
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-01-01 → 2022-06-30 | ¥82.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-06-30 | ¥43.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-01-01 → 2022-06-30 | ¥62.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-06-30 | ¥32.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-01-01 → 2022-06-30 | ¥20.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥11.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-01-01 → 2022-06-30 | ¥7.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-06-30 | ¥3.8bn |
| Reconciling Itemsreconciling | revenue | 2022-01-01 → 2022-06-30 | −¥20.1bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥11.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-01 → 2022-06-30 | −¥20.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥11.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-06-30 | −¥22.8bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥11.1bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥16.7bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥9.0bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥16.7bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥9.0bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2022-01-01 → 2022-06-30 | ¥5m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥2m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥1.8bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥2.0bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥205.8bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥115.4bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥205.8bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥115.4bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2022-01-01 → 2022-06-30 | ¥11m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥7m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥28.1bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥16.9bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥529.3bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥277.2bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥529.3bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥277.2bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥52.2bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥34.9bn |
| —segment total | revenue | 2022-01-01 → 2022-06-30 | ¥834.4bn |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥445.3bn |
| —segment total | revenue external | 2022-01-01 → 2022-06-30 | ¥814.3bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥434.0bn |
| —segment total | revenue intersegment | 2022-01-01 → 2022-06-30 | ¥20.1bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥11.3bn |
| —segment total | segment profit | 2022-01-01 → 2022-06-30 | ¥90.0bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥57.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-01-01 → 2021-06-30 | ¥73.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-06-30 | ¥38.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-01-01 → 2021-06-30 | ¥55.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-06-30 | ¥28.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-01-01 → 2021-06-30 | ¥18.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥10.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-01-01 → 2021-06-30 | ¥9.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-06-30 | ¥4.3bn |
| Reconciling Itemsreconciling | revenue | 2021-01-01 → 2021-06-30 | −¥18.1bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥10.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-01-01 → 2021-06-30 | −¥18.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥10.0bn |
| Reconciling Itemsreconciling | segment profit | 2021-01-01 → 2021-06-30 | −¥21.8bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥10.9bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2021-01-01 → 2021-06-30 | ¥15.2bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥8.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2021-01-01 → 2021-06-30 | ¥15.2bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥8.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2021-01-01 → 2021-06-30 | ¥9m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥5m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2021-01-01 → 2021-06-30 | ¥3.3bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥1.2bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2021-01-01 → 2021-06-30 | ¥175.3bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥98.5bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2021-01-01 → 2021-06-30 | ¥175.3bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥98.4bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2021-01-01 → 2021-06-30 | ¥20m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥11m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2021-01-01 → 2021-06-30 | ¥26.8bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥18.1bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2021-01-01 → 2021-06-30 | ¥472.5bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥247.1bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2021-01-01 → 2021-06-30 | ¥472.5bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥247.1bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2021-01-01 → 2021-06-30 | ¥93.5bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥48.4bn |
| —segment total | revenue | 2021-01-01 → 2021-06-30 | ¥736.9bn |
| —segment total | revenue | 2021-04-01 → 2021-06-30 | ¥392.0bn |
| —segment total | revenue external | 2021-01-01 → 2021-06-30 | ¥718.8bn |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥382.0bn |
| —segment total | revenue intersegment | 2021-01-01 → 2021-06-30 | ¥18.1bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥10.0bn |
| —segment total | segment profit | 2021-01-01 → 2021-06-30 | ¥133.0bn |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥72.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 858
| Item | Context | Value | Unit |
|---|---|---|---|
| Intersegment revenue IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 5000000 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 9960000000 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration_ReportableSegmentsMember | 9977000000 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration_ReconcilingItemsMember | -9977000000 | JPY |
| Intersegment revenue IFRS | Prior1QuarterDuration | － | JPY |
| Revenue IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 247144000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 98456000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 8380000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 38022000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_ReportableSegmentsMember | 392004000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration_ReconcilingItemsMember | -9977000000 | JPY |
| Revenue IFRS | Prior1QuarterDuration | 382026000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 48447000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 18126000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 1172000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4261000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_ReportableSegmentsMember | 72007000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_ReconcilingItemsMember | -10930000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration | 61076000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 277235000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 115422000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 8993000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 32347000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 433998000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration | 433998000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 7000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 2000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 11272000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 11282000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_ReconcilingItemsMember | -11282000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration | － | JPY |
| Revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 277235000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 115429000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 8996000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 43619000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 445280000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_ReconcilingItemsMember | -11282000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration | 433998000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 34860000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 16870000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 1985000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 3821000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 57537000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_ReconcilingItemsMember | -11140000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration | 46396000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |